I-MAB SPONS.ADS/1 -0001 (0VY) - Total Assets
Based on the latest financial reports, I-MAB SPONS.ADS/1 -0001 (0VY) holds total assets worth €260.52 Million EUR (≈ $304.58 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore I-MAB SPONS.ADS/1 -0001 debt service capacity to assess how comfortably operating cash covers total debt obligations.
I-MAB SPONS.ADS/1 -0001 - Total Assets Trend (2021–2025)
This chart illustrates how I-MAB SPONS.ADS/1 -0001's total assets have evolved over time, based on quarterly financial data. See what is I-MAB SPONS.ADS/1 -0001's book value for net asset value and shareholders' equity analysis.
I-MAB SPONS.ADS/1 -0001 - Asset Composition Analysis
Current Asset Composition (December 2025)
I-MAB SPONS.ADS/1 -0001's total assets of €260.52 Million consist of 83.5% current assets and 16.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 80.9% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how I-MAB SPONS.ADS/1 -0001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see I-MAB SPONS.ADS/1 -0001 stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: I-MAB SPONS.ADS/1 -0001's current assets represent 83.5% of total assets in 2025, a decrease from 85.4% in 2021.
- Cash Position: Cash and equivalents constituted 80.9% of total assets in 2025, up from 62.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
I-MAB SPONS.ADS/1 -0001 Competitors by Total Assets
Key competitors of I-MAB SPONS.ADS/1 -0001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
I-MAB SPONS.ADS/1 -0001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.09 | 20.90 | 15.99 |
| Quick Ratio | 8.09 | 20.90 | 15.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €190.63 Million | €168.24 Million | €176.44 Million |
I-MAB SPONS.ADS/1 -0001 - Advanced Valuation Insights
This section examines the relationship between I-MAB SPONS.ADS/1 -0001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.09 |
| Latest Market Cap to Assets Ratio | 0.79 |
| Asset Growth Rate (YoY) | 22.5% |
| Total Assets | €260.52 Million |
| Market Capitalization | $206.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values I-MAB SPONS.ADS/1 -0001's assets below their book value (0.79x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: I-MAB SPONS.ADS/1 -0001's assets grew by 22.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for I-MAB SPONS.ADS/1 -0001 (2021–2025)
The table below shows the annual total assets of I-MAB SPONS.ADS/1 -0001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €260.52 Million ≈ $304.58 Million |
+22.49% |
| 2024-12-31 | €212.68 Million ≈ $248.65 Million |
-42.35% |
| 2023-12-31 | €368.92 Million ≈ $431.31 Million |
-37.52% |
| 2022-12-31 | €590.45 Million ≈ $690.29 Million |
-32.81% |
| 2021-12-31 | €878.74 Million ≈ $1.03 Billion |
-- |
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more